| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6095333 | Gastroenterology | 2014 | 10 Pages |
Abstract
Based on a phase 2 trial, the glutenase ALV003 appears to attenuate gluten-induced small intestinal mucosal injury in patients with celiac disease in the context of an everyday gluten-free diet containing daily up to 2 g gluten. Clinicaltrial.gov, Numbers: NCT00959114 and NCT01255696.
Keywords
VASDGPTG2GSRSEMAIELEndomysial antibodyUpper gastrointestinal endoscopyOctDuodenal biopsyTransglutaminase 2Enzyme-linked immunosorbent assayELISADrug treatmentoptimal cutting temperatureadverse eventIntraepithelial lymphocytevisual analogue scaleGastrointestinal Symptom Rating ScaleMorphometryUGEdeamidated gliadin peptideClinical trial
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Marja-Leena Lähdeaho, Katri Kaukinen, Kaija Laurila, Pekka Vuotikka, Olli-Pekka Koivurova, Tiina Kärjä-Lahdensuu, Annette Marcantonio, Daniel C. Adelman, Markku Mäki,